INVO Fertility, Inc. (IVF): debt financing — INVO Bioscience sells $543,750 receivables for $375K; cancels 150K-share warrant

On July 20, 2023, INVO Bioscience, Inc. (the “Company”) entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with Cedar Advance LLC (“Cedar”) under which Cedar purchased $543,750 of our receivables for a gross purchase price of $375,000.

JAG Amended Letter Agreement On July 21, 2023 the Company entered into an amended and restated letter agreement (the “Amended Letter Agreement”) with JAG Multi Investments LLC (“JAG”) to restate the terms of that certain July 10, 2023 letter agreement between the Company and JAG (the “Original Letter Agreement”). The Amended Letter Agreement removes all references to issuance of a new warrant and repricing of warrants referenced in the Original Letter Agreement, both of which are void ab initio. Since the parties agreed that the warrant issuance to JAG referred to in the Original Letter Agreement is void ab initio, the July 10, 2023 warrant to purchase 150,000 shares of common stock of the Company to JAG is rescinded and cancelled and of no force and effect.

July 2023 Standard Merchant Cash Advance Agreement On July 20, 2023, INVO Bioscience, Inc. (the “Company”) entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with Cedar Advance LLC (“Cedar”) under which Cedar purchased $543,750 of our receivables for a gross purchase price of $375,000. We received net proceeds of $356,250. Until the purchase price has been repaid, we agreed to pay Cedar $19,419.64 per week. If we repay the purchase price within 30-days then the amount payable shall be reduced to $465,000. In addition, we granted Cedar a security interest in our accounts, including deposit accounts and accounts receivable. We intend to use the proceeds for working capital and general corporate purposes.